Evidence map›Paper›PMID 28693586›Full record

ArticleJournal of translational medicine2017

Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.

Meghali Goswami, Gabrielle Prince, Angelique Biancotto, Susan Moir, Lela Kardava, Brian H Santich, Foo Cheung, Yuri Kotliarov, Jinguo Chen, Rongye Shi and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Meghali GoswamiMyeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive Room 10CRC 5-5216, Bethesda, MD, 20814-1476, USA. meg.goswami@nih.gov.ORCID 0000-0001-6661-3190
Gabrielle PrinceJohns Hopkins University, Baltimore, MD, USA.
Angelique BiancottoCenter for Human Immunology, Autoimmunity and Inflammation, National Institutes of Health, Bethesda, MD, USA.
Susan MoirNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Lela KardavaNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Brian H SantichNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Foo CheungCenter for Human Immunology, Autoimmunity and Inflammation, National Institutes of Health, Bethesda, MD, USA.
Yuri KotliarovCenter for Human Immunology, Autoimmunity and Inflammation, National Institutes of Health, Bethesda, MD, USA.
Jinguo ChenCenter for Human Immunology, Autoimmunity and Inflammation, National Institutes of Health, Bethesda, MD, USA.
Rongye ShiCenter for Human Immunology, Autoimmunity and Inflammation, National Institutes of Health, Bethesda, MD, USA.
Huizhi ZhouCenter for Human Immunology, Autoimmunity and Inflammation, National Institutes of Health, Bethesda, MD, USA.
Hana GoldingDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Jody ManischewitzDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Lisa KingDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Lauren M KunzOffice of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Kimberly NoonanJohns Hopkins University, Baltimore, MD, USA.
Ivan M BorrelloJohns Hopkins University, Baltimore, MD, USA.
B Douglas SmithJohns Hopkins University, Baltimore, MD, USA.
Christopher S HouriganMyeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive Room 10CRC 5-5216, Bethesda, MD, 20814-1476, USA.
National Institutes of Health · USJohns Hopkins University · USCenter for Biologics Evaluation and Research · US

Funding

Center for Human Immunology ZICAI001226 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2018 to 2025
$34.1M
Role of B Lymphocytes In HIV Infection And PathogenesisZIAAI000825 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOIR, SUSAN · 2009 to 2025
$24.5M
Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.ZIAHL006163 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HOURIGAN, CHRISTOPHER · 2013 to 2023
$21.0M
6 · The paper itself

Abstract

backgroundChanges in adaptive immune cells after chemotherapy in adult acute myeloid leukemia (AML) may have implications for the success of immunotherapy. This study was designed to determine the functional capacity of the immune system in adult patients with AML who have completed chemotherapy and are potential candidates for immunotherapy.

methodsWe used the response to seasonal influenza vaccination as a surrogate for the robustness of the immune system in 10 AML patients in a complete remission post-chemotherapy and performed genetic, phenotypic, and functional characterization of adaptive immune cell subsets.

resultsOnly 2 patients generated protective titers in response to vaccination, and a majority of patients had abnormal frequencies of transitional and memory B-cells. B-cell receptor sequencing showed a B-cell repertoire with little evidence of somatic hypermutation in most patients. Conversely, frequencies of T-cell populations were similar to those seen in healthy controls, and cytotoxic T-cells demonstrated antigen-specific activity after vaccination. Effector T-cells had increased PD-1 expression in AML patients least removed from chemotherapy.

conclusionOur results suggest that while some aspects of cellular immunity recover quickly, humoral immunity is incompletely reconstituted in the year following intensive cytotoxic chemotherapy for AML. The observed B-cell abnormalities may explain the poor response to vaccination often seen in AML patients after chemotherapy. Furthermore, the uncoupled recovery of B-cell and T-cell immunity and increased PD-1 expression shortly after chemotherapy might have implications for the success of several modalities of immunotherapy.

Indexed as

ImmunityAdultAgedAntibodies, ViralB-LymphocytesConsolidation ChemotherapyDemographyFemaleHumansImmunologic MemoryInfluenza VaccinesLeukemia, Myeloid, AcuteLymphocyte CountMaleMiddle AgedProgrammed Cell Death 1 ReceptorAntibodies, ViralInfluenza VaccinesPDCD1 protein, humanProgrammed Cell Death 1 ReceptorAdaptive immunityB-cellsImmunotherapyInfluenza vaccinationLeukemiaT-cells

Identifiers

PMID28693586
PMCPMC5504716
OpenAlexW2735429607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.